A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity

References

• Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubat T, Yagita H, Honjo T. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996;8(5):765–13. doi:10.1093/intimm/8.5.765.
   PubMed Web of Science ®Google Scholar
• Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, Sasmal DK, Huang J, Kim JM, Mellman I. et al. T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition. Science. 2017;355(6332):1428–1433. doi:10.1126/science.aaf1292.
   PubMed Web of Science ®Google Scholar
• Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N. et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291(5502):319–322. doi:10.1126/science.291.5502.319.
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027–1034. doi:10.1084/jem.192.7.1027.
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800. doi:10.1038/nm730.
   PubMed Web of Science ®Google Scholar
• Li K, Yuan Z, Lyu J, Ahn E, Davis SJ, Ahmed R, Zhu C. PD-1 suppresses TCR-CD8 cooperativity during T-cell antigen recognition. Nat Commun. 2021;12(1):2746. doi:10.1038/s41467-021-22965-9.
   PubMed Web of Science ®Google Scholar
• Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M, Saito T. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med. 2012;209(6):1201–1217. doi:10.1084/jem.20112741.
   PubMed Web of Science ®Google Scholar
• Ostrand-Rosenberg S, Horn LA, Haile ST. The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. J Immunol. 2014;193(8):3835–3841. doi:10.4049/jimmunol.1401572.
   PubMed Web of Science ®Google Scholar
• Kuchroo JR, Hafler DA, Sharpe AH, Lucca LE. The double-edged sword: harnessing PD-1 blockade in tumor and autoimmunity. Sci Immunol. 2021;6(65):eabf4034. doi:10.1126/sciimmunol.abf4034.
   PubMed Web of Science ®Google Scholar
• Wei SC, Duffy CR, Allison JP. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov. 2018;8(9):1069–1086. doi:10.1158/2159-8290.CD-18-0367.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K. et al. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–2465. doi:10.1056/NEJMoa1200694.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB. et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. doi:10.1056/NEJMoa1200690.
   PubMed Web of Science ®Google Scholar
• Yap TA, Parkes EE, Peng W, Moyers JT, Curran MA, Tawbi HA. Development of immunotherapy combination strategies in cancer. Cancer Discov. 2021;11(6):1368–1397. doi:10.1158/2159-8290.CD-20-1209.
   PubMed Web of Science ®Google Scholar
• Chae YK, Arya A, Iams W, Cruz MR, Chandra S, Choi J, Giles F. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer. 2018;6(1):39. doi:10.1186/s40425-018-0349-3.
   PubMed Web of Science ®Google Scholar
• Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su M-J, Melms JC, Leeson R, Kanodia A, Mei S, Lin J-R. et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. Cell. 2018;175(4):984–997 e924. doi:10.1016/j.cell.2018.09.006.
   PubMed Web of Science ®Google Scholar
• Weiss SA, Sznol M. Resistance mechanisms to checkpoint inhibitors. Curr Opin Immunol. 2021;69:47–55. doi:10.1016/j.coi.2021.02.001.
   PubMed Web of Science ®Google Scholar
• Nie S, Wang Z, Moscoso-Castro M, D’Souza P, Lei C, Xu J, Gu J. Biology drives the discovery of bispecific antibodies as innovative therapeutics. Antib Ther. 2020;3(1):18–62. doi:10.1093/abt/tbaa003.
   PubMedGoogle Scholar
• Syed YY. Amivantamab: first approval. Drugs. 2021;81(11):1349–1353. doi:10.1007/s40265-021-01561-7.
   PubMed Web of Science ®Google Scholar
• Kang C. Mosunetuzumab: first approval. Drugs. 2022;82(11):1229–1234. doi:10.1007/s40265-022-01749-5.
   PubMed Web of Science ®Google Scholar
• Keam SJ. Cadonilimab: first approval. Drugs. 2022;82(12):1333–1339. doi:10.1007/s40265-022-01761-9.
   PubMed Web of Science ®Google Scholar
• Zakeri B, Fierer JO, Celik E, Chittock EC, Schwarz-Linek U, Moy VT, Howarth M. Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. Proc Natl Acad Sci USA. 2012;109(12):E690–697. doi:10.1073/pnas.1115485109.
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994;179(4):1109–1118. doi:10.1084/jem.179.4.1109.
   PubMed Web of Science ®Google Scholar
• Eskiocak U, Guzman W, Wolf B, Cummings C, Milling L, Wu H-J, Ophir M, Lambden C, Bakhru P, Gilmore DC. et al. Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity. JCI Insight. 2020;5(5). doi:10.1172/jci.insight.133647.
   PubMed Web of Science ®Google Scholar
• Park JJ, Thi EP, Carpio VH, Bi Y, Cole AG, Dorsey BD, Fan K, Harasym T, Iott CL, Kadhim S. et al. Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1. Nat Commun. 2021;12(1):1222. doi:10.1038/s41467-021-21410-1.
   PubMed Web of Science ®Google Scholar
• Jin Y, An X, Mao B, Sun R, Kumari R, Chen X, Shan Y, Zang M, Xu L, Muntel J. et al. Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment. Sci Rep. 2022;12(1):3278. doi:10.1038/s41598-022-07153-z.
   PubMed Web of Science ®Google Scholar
• Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27(1):111–122. doi:10.1016/j.immuni.2007.05.016.
   PubMed Web of Science ®Google Scholar
• Burrack AL, Spartz EJ, Raynor JF, Wang I, Olson M, Stromnes IM. Combination PD-1 and PD-L1 Blockade promotes durable neoantigen-specific T Cell-mediated immunity in pancreatic ductal adenocarcinoma. Cell Rep. 2019;28(8):2140–2155 e2146. doi:10.1016/j.celrep.2019.07.059.
   PubMed Web of Science ®Google Scholar
• Ngiow SF, Young A, Jacquelot N, Yamazaki T, Enot D, Zitvogel L, Smyth MJ. A threshold level of intratumor CD8+ T-cell PD1 expression dictates therapeutic response to anti-PD1. Cancer Res. 2015;75(18):3800–3811. doi:10.1158/0008-5472.CAN-15-1082.
   PubMed Web of Science ®Google Scholar
• Kotanides H, Li Y, Malabunga M, Carpenito C, Eastman SW, Shen Y, Wang G, Inigo I, Surguladze D, Pennello AL. et al. Bispecific targeting of PD-1 and PD-L1 enhances T-cell activation and antitumor immunity. Cancer Immunol Res. 2020;8(10):1300–1310. doi:10.1158/2326-6066.CIR-20-0304.
   PubMed Web of Science ®Google Scholar
• Orme JJ, Jazieh KA, Xie T, Harrington S, Liu X, Ball M, Madden B, Charlesworth MC, Azam TU, Lucien F. et al. ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance. Oncoimmunology. 2020;9(1):1744980. doi:10.1080/2162402X.2020.1744980.
   PubMed Web of Science ®Google Scholar
• Hayashida K, Bartlett AH, Chen Y, Park PW. Molecular and cellular mechanisms of ectodomain shedding. Anat Rec (Hoboken). 2010;293(6):925–937. doi:10.1002/ar.20757.
   PubMedGoogle Scholar
• Fransen MF, Schoonderwoerd M, Knopf P, Camps MGM, Hawinkels LJAC, Kneilling M, van Hall T, Ossendorp F. Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy. JCI Insight. 2018;3(23). doi:10.1172/jci.insight.124507.
   PubMed Web of Science ®Google Scholar
• Khan M, Zhao Z, Arooj S, Fu Y, Liao G. Soluble PD-1: predictive, prognostic, and therapeutic value for cancer immunotherapy. Front Immunol. 2020;11:587460. doi:10.3389/fimmu.2020.587460.
   PubMed Web of Science ®Google Scholar
• Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ. et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24–34. doi:10.1056/NEJMoa2109970.
   PubMed Web of Science ®Google Scholar
• Nakajima EC, Vellanki PJ, Larkins E, Chatterjee S, Mishra-Kalyani PS, Bi Y, Qosa H, Liu J, Zhao H, Biable M. et al. FDA approval summary: nivolumab in combination with ipilimumab for the treatment of unresectable malignant pleural mesothelioma. Clin Cancer Res. 2022;28(3):446–451. doi:10.1158/1078-0432.CCR-21-1466.
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS. et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–2017. doi:10.1056/NEJMoa1414428.
   PubMed Web of Science ®Google Scholar